A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

GlaxoSmithKline (GSK)

Status

Completed

Conditions

Rhinitis, Allergic, Perennial

Treatments

Drug: fluticasone propionate

Drug: mometasone furoate

Drug: Fluticasone furoate

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT01199757

114812

Details and patient eligibility

About

Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both ocular and nasal symptoms have a greater burden of illness and lower quality of life than patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both nasal and ocular symptoms. The purpose of this study was to evaluate the differences in symptom control (both perceptually and objectively) and resource use for patients with current seasonal AR.

Full description

Allergic rhinitis (AR) is a common inflammatory condition of the upper respiratory tract, nasal cavity and eyes affecting up to 20% of the population in the United States and Europe. The bothersome nature of AR symptoms can severely affect daily activities including ability to work and examination performance and impact on quality of life (QoL) and psychosocial well being.
This study assesses the impact of Fluticasone furoate (FF) on the QoL of seasonal allergic rhinitis (SAR) patients, including the number of symptom-free days (SFD) and quality of life over the last 4 weeks, and compares this with other inhaled nasal steroids (INS): mometasone furate (MF) and fluticasone proprionate (FP).
Selected physicians provide information including a range of demographic, symptom and treatment details for a number of their SAR patients. The patient themselves are then invited to provide details about their SAR including symptoms, the impact of AR upon their lifestyles, attitudes to treatment and completion of Health Related Quality of Life (HRQoL) instruments.

Enrollment

540 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Patient Inclusion Criteria:

Current Seasonal Allergic Rhinitis sufferer (based on physician judgement)
Currently receiving prescribed INS treatment (no other treatment restrictions apply)
Have consumed at least one full prescription on the specified INS treatment
No comorbid Asthma or COPD diagnosis
Informed Consent

Exclusion Criteria: